Piperacillin Tazobactam – Injection products
Recognized Interpretive Criteria
FDA Identified Interpretive Criteria
|
Minimum Inhibitory |
Disk Diffusion |
||||
---|---|---|---|---|---|---|
Pathogen |
S |
I |
R |
S |
I |
R |
Enterobacterales* |
≤8/4 |
16/4 |
≥32/4 |
≥25 |
21-24 |
≤20 |
Pseudomonas aeruginosa |
≤16/4 |
32/4-64/4 |
≥128/4 |
≥21 |
15-20 |
≤14 |
Acinetobacter spp. |
M100 standard is recognized |
|||||
Haemophilus influenzae and parainfluenzae |
M100 standard is recognized |
|||||
Anaerobes |
M100 standard is recognized |
- |
- |
- |
S = Susceptible; I = Intermediate; R = Resistant
*Clinical efficacy was shown for E. coli and K. pneumoniae
Exception to the recognized standard of CLSI M100
For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:
Other Non-Enterobacterales